PR Newswire

AbbVie Presents Data for ABBV-466, a Novel Dual-Targeting Therapy Demonstrating Higher Endoscopic Remission Rates Than Either Anti-IL-23 or Anti-α4β7 Monotherapy in Moderate ...

In a Phase 2a study, ABBV-466 achieved higher endoscopic remission rates in patients with Crohn's disease than either anti-IL-23 p19 or anti-α4β7 ...
Fierce Biotech

AbbVie’s next-gen Crohn’s disease combo beats Skyrizi in phase 2 trial

AbbVie’s next-generation Crohn’s disease combination candidate has beaten Skyrizi in a midphase clinical trial. Skyrizi is a ...
MarketScreener

AbbVie Presents Data For ABBV-466 Demonstrating Higher Endoscopic Remission Rates Than Either Anti-IL-23 Or Anti-a4ß7 Monotherapy In Moderate To Severe Crohn's Disease

TARGET-CD (NCT06548542) is an ongoing open-label, treat-through Phase 2a platform study in patients with moderate-to-severe Crohn's disease. Patients were randomized 1:1:1 to receive 24 weeks of ...
Cancer Network

Colon Cancer Treatment Algorithm

Aparna Parikh, MD, and the Oncology Brothers have a comprehensive discussion on treatment decision-making practices for patients with colon cancer, highlighting considerations such as high ...
Forbes

Convert United States Dollar To Costa Rican Colón

Use our currency converter to find the live exchange rate between USD and CRC. Convert United States Dollar to Costa Rican Colón ...